January 22, 2018 / 7:33 AM / a month ago

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

Jan 22 (Reuters) - NANOBIOTIX SA:

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

* VERY GOOD SAFETY PROFILE WITH NO AES AND SAES RELATED TO NBTXR3

* THIRD INDICATION IN GLOBAL NBTXR3 DEVELOPMENT CONFIRMING TRANSFERABILITY ACROSS DIFFERENT CANCERS

* ‍COMPLETE RESPONSE ACHIEVED IN 3 OUT OF 7 PATIENTS EVALUABLE​

* ‍PARTIAL RESPONSE ACHIEVED IN 3 OUT OF 7 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below